Cancer's Epicentre: Cancer and Epigenetics  

Oleh:

[s.n]

Jenis: Article from Bulletin/Magazine
Dalam koleksi: The Economist (http://search.proquest.com/) vol. 403 no. 8779 (Apr. 2012), page 73-74.
Topik: Cancer; Medical Research; Genetics; Drugs; Deoxyribonucleic Acid--DNA

Ketersediaan

Perpustakaan Pusat (Semanggi) Nomor Panggil: EE29.71 Non-tandon: 1 (dapat dipinjam: 0) Tandon: tidak ada

Lihat Detail Induk

Isi artikel

The biggest conceptual breakthrough in the war on cancer was the realization by the 1980s that it is always a genetic disease. Sometimes the genetic flaw is inherited. Sometimes it is the result of exposure to an outside agent such as tobacco smoke or radioactivity. Sometimes it is plain bad luck. Turning that breakthrough into medicine, though, is hard. Researchers led by Stephen Baylin at Johns Hopkins School of Medicine, in Baltimore, have shown that a combination of a histone-deacetylase inhibitor and azacitidine slowed tumour growth in some people with advanced lung cancer. It was the first time epigenetic drugs had been deployed successfully against a solid tumor, rather than a leukaemia or a lymphoma (solid tumors are harder to treat, because the drug has to penetrate them). Epigenetics might justly take its place alongside genetics in the analysis and treatment of cancer.

Opini Anda

Klik untuk menuliskan opini Anda tentang koleksi ini!

Kembali